Identification of an HIV-1 replication inhibitor which rescues host restriction factor APOBEC3G in Vif-APOBEC3G complex

Antiviral Research

Volumn 122, Issue , 2015, Pages 20-27

  Zhang, Shaoyang ^a   Zhong, Limei ^b   Chen, Bing ^a   Pan, Ting ^a   Zhang, Xue ^a   Liang, Liting ^a   Li, Qianwen ^a   Zhang, Ziying ^c   Chen, Hui ^a   Zhou, Jie ^a   Luo, Haihua ^a   Zhang, Hui ^a   Bai, Chuan ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG SECOND PROVINCIAL GENERAL HOSPITAL   (China)

^c Guangzhou Molcalx Information and Technology Ltd   (China)

Author keywords

APOBEC3G; Elongin C; HIV 1; Vif; ZBMA 1

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CULLIN; CULLIN 5; ELONGIN B; ELONGIN C; UNCLASSIFIED DRUG; VIF PROTEIN; ZBMA 1; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOBEC3G PROTEIN, HUMAN; CUL5 PROTEIN, HUMAN; CYTIDINE DEAMINASE; ELONGIN; TRANSCRIPTION FACTOR; VIF PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC50; IMMUNOPRECIPITATION; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; VIRUS GENOME; VIRUS REPLICATION; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HIV INFECTIONS; METABOLISM; PHYSIOLOGY; SYNTHESIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ANTI-HIV AGENTS; CULLIN PROTEINS; CYTIDINE DEAMINASE; DRUG DISCOVERY; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOPRECIPITATION; MICE; MOLECULAR DOCKING SIMULATION; TRANSCRIPTION FACTORS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84938863802     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.07.009     Document Type: Article

References (35)

1. C.S. Adamson, and E.O. Freed Novel approaches to inhibiting HIV-1 replication Antiviral Res. 85 2010 119 141
2. F. Aires da Silva, M. Santa-Marta, A. Freitas-Vieira, P. Mascarenhas, I. Barahona, J. Moniz-Pereira, D. Gabuzda, and J. Goncalves Camelized rabbit-derived VH single-domain intrabodies against Vif strongly neutralize HIV-1 infectivity J. Mol. Biol. 340 2004 525 542
3. A. Ali, J. Wang, R.S. Nathans, H. Cao, N. Sharova, M. Stevenson, and T.M. Rana Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication ChemMedChem 7 2012 1217 1229
4. John A. Barltro, T.C. Owen, Ann H. Cory, and Joseph G. Cory 5-(3-carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulfophenyl)tetrazolium, inner salt (MTS) and related analogs of 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans As cell-viability indicators Bioorg. Med. Chem. Lett. 1 1991 611 614
5. S. Cen, Z.G. Peng, X.Y. Li, Z.R. Li, J. Ma, Y.M. Wang, B. Fan, X.F. You, Y.P. Wang, F. Liu, R.G. Shao, L.X. Zhao, L. Yu, and J.D. Jiang Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G J. Biol. Chem. 285 2010 16546 16552
6. A.H. Cory, T.C. Owen, J.A. Barltrop, and J.G. Cory Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture Cancer Commun. 3 1991 207 212
7. D.H. Gabuzda, K. Lawrence, E. Langhoff, E. Terwilliger, T. Dorfman, W.A. Haseltine, and J. Sodroski Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes J. Virol. 66 1992 6489 6495
8. Y. Guo, L. Dong, X. Qiu, Y. Wang, B. Zhang, H. Liu, Y. Yu, Y. Zang, M. Yang, and Z. Huang Structural basis for hijacking CBF-beta and CUL5 E3 ligase complex by HIV-1 Vif Nature 505 2014 229 233
9. R.S. Harris, K.N. Bishop, A.M. Sheehy, H.M. Craig, S.K. Petersen-Mahrt, I.N. Watt, M.S. Neuberger, and M.H. Malim DNA deamination mediates innate immunity to retroviral infection Cell 113 2003 803 809
10. R.K. Holmes, M.H. Malim, and K.N. Bishop APOBEC-mediated viral restriction: not simply editing? Trends Biochem. Sci. 32 2007 118 128
11. S. Jager, P. Cimermancic, N. Gulbahce, J.R. Johnson, K.E. McGovern, S.C. Clarke, M. Shales, G. Mercenne, L. Pache, K. Li, H. Hernandez, G.M. Jang, S.L. Roth, E. Akiva, J. Marlett, M. Stephens, I. D'Orso, J. Fernandes, M. Fahey, C. Mahon, A.J. O'Donoghue, A. Todorovic, J.H. Morris, D.A. Maltby, T. Alber, G. Cagney, F.D. Bushman, J.A. Young, S.K. Chanda, W.I. Sundquist, T. Kortemme, R.D. Hernandez, C.S. Craik, A. Burlingame, A. Sali, A.D. Frankel, and N.J. Krogan Global landscape of HIV-human protein complexes Nature 481 2012 365 370
12. D. Lecossier, F. Bouchonnet, F. Clavel, and A.J. Hance Hypermutation of HIV-1 DNA in the absence of the Vif protein Science 300 2003 1112
13. M. Li, S.M. Shandilya, M.A. Carpenter, A. Rathore, W.L. Brown, A.L. Perkins, D.A. Harki, J. Solberg, D.J. Hook, K.K. Pandey, M.A. Parniak, J.R. Johnson, N.J. Krogan, M. Somasundaran, A. Ali, C.A. Schiffer, and R.S. Harris First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G ACS Chem. Biol. 7 2012 506 517
14. C. Liu, X. Zhang, F. Huang, B. Yang, J. Li, B. Liu, H. Luo, P. Zhang, and H. Zhang APOBEC3G inhibits microRNA-mediated repression of translation by interfering with the interaction between Argonaute-2 and MOV10 J. Biol. Chem. 287 2012 29373 29383
15. B. Mangeat, P. Turelli, G. Caron, M. Friedli, L. Perrin, and D. Trono Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts Nature 424 2003 99 103
16. R. Mariani, D. Chen, B. Schrofelbauer, F. Navarro, R. Konig, B. Bollman, C. Munk, H. Nymark-McMahon, and N.R. Landau Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif Cell 114 2003 21 31
17. M. Marin, K.M. Rose, S.L. Kozak, and D. Kabat HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation Nat. Med. 9 2003 1398 1403
18. A. Mehle, J. Goncalves, M. Santa-Marta, M. McPike, and D. Gabuzda Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation Genes Dev. 18 2004 2861 2866
19. A. Mehle, B. Strack, P. Ancuta, C. Zhang, M. McPike, and D. Gabuzda Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway J. Biol. Chem. 279 2004 7792 7798
20. E.J. Mills, J.B. Nachega, D.R. Bangsberg, S. Singh, B. Rachlis, P. Wu, K. Wilson, I. Buchan, C.J. Gill, and C. Cooper Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators PLoS Med. 3 2006 e438
21. R. Nathans, H. Cao, N. Sharova, A. Ali, M. Sharkey, R. Stranska, M. Stevenson, and T.M. Rana Small-molecule inhibition of HIV-1 Vif Nat. Biotechnol. 26 2008 1187 1192
22. T. Pan, S. Wu, X. He, H. Luo, Y. Zhang, M. Fan, G. Geng, V.C. Ruiz, J. Zhang, L. Mills, C. Bai, and H. Zhang Necroptosis takes place in human immunodeficiency virus type-1 (HIV-1)-infected CD4+ T lymphocytes PLoS ONE 9 2014 e93944
23. D.D. Richman, S.C. Morton, T. Wrin, N. Hellmann, S. Berry, M.F. Shapiro, and S.A. Bozzette The prevalence of antiretroviral drug resistance in the United States AIDS 18 2004 1393 1401
24. L. Ross, M.L. Lim, Q. Liao, B. Wine, A.E. Rodriguez, W. Weinberg, and M. Shaefer Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naive HIV-infected individuals from 40 United States cities HIV Clin. Trials 8 2007 1 8
25. A.M. Sheehy, N.C. Gaddis, J.D. Choi, and M.H. Malim Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein Nature 418 2002 646 650
26. A.M. Sheehy, N.C. Gaddis, and M.H. Malim The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif Nat. Med. 9 2003 1404 1407
27. K. Stopak, C. de Noronha, W. Yonemoto, and W.C. Greene HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability Mol. Cell 12 2003 591 601
28. R. Suspene, P. Sommer, M. Henry, S. Ferris, D. Guetard, S. Pochet, A. Chester, N. Navaratnam, S. Wain-Hobson, and J.P. Vartanian APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase Nucleic Acids Res. 32 2004 2421 2429
29. Z. Xiao, E. Ehrlich, Y. Yu, K. Luo, T. Wang, C. Tian, and X.F. Yu Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif Virology 349 2006 290 299
30. X. Yu, Y. Yu, B. Liu, K. Luo, W. Kong, P. Mao, and X.F. Yu Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex Science 302 2003 1056 1060
31. Q. Yu, R. Konig, S. Pillai, K. Chiles, M. Kearney, S. Palmer, D. Richman, J.M. Coffin, and N.R. Landau Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome Nat. Struct. Mol. Biol. 11 2004 435 442
32. Y. Yu, Z. Xiao, E.S. Ehrlich, X. Yu, and X.F. Yu Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines Genes Dev. 18 2004 2867 2872
33. H. Zhang, B. Yang, R.J. Pomerantz, C. Zhang, S.C. Arunachalam, and L. Gao The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA Nature 424 2003 94 98
34. W. Zhang, J. Du, S.L. Evans, Y. Yu, and X.F. Yu T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction Nature 481 2012 376 379
35. T. Zuo, D. Liu, W. Lv, X. Wang, J. Wang, M. Lv, W. Huang, J. Wu, H. Zhang, H. Jin, L. Zhang, W. Kong, and X. Yu Small-molecule inhibition of human immunodeficiency virus type 1 replication by targeting the interaction between Vif and Elongin C J. Virol. 86 2012 5497 5507